167 related articles for article (PubMed ID: 26481697)
1. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
Yan H; Li Q; Wang W; Zhen H; Cao B
Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Xu JL; Jin B; Ren ZH; Lou YQ; Zhou ZR; Yang QZ; Han BH
PLoS One; 2015; 10(7):e0131278. PubMed ID: 26147288
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.
Li N; Yang L; Ou W; Zhang L; Zhang SL; Wang SY
PLoS One; 2014; 9(7):e102777. PubMed ID: 25029199
[TBL] [Abstract][Full Text] [Related]
4. Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials.
Vale CL; Burdett S; Fisher DJ; Navani N; Parmar MK; Copas AJ; Tierney JF
Clin Lung Cancer; 2015 May; 16(3):173-182.e4. PubMed ID: 25547901
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials.
Lai X; Zeng J; Xiao Z; Xiao J
Medicine (Baltimore); 2024 Jun; 103(23):e38277. PubMed ID: 38847673
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials.
Liu R; Wei S; Zhang Q; Zhang X; Luo H; Tian J; Li Y; Ge L; Wang X
Medicine (Baltimore); 2019 Jul; 98(29):e16427. PubMed ID: 31335695
[TBL] [Abstract][Full Text] [Related]
7. Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis.
Yang XQ; Li CY; Xu MF; Zhao H; Wang D
BMC Cancer; 2015 Dec; 15():949. PubMed ID: 26673747
[TBL] [Abstract][Full Text] [Related]
8. Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer.
Xiao N; He H; Wang J; Zhang L; Chow B; Feng F; Xu Y; Huang J; Zhou X; Dong R
J Evid Based Integr Med; 2021; 26():2515690X211010733. PubMed ID: 33926244
[TBL] [Abstract][Full Text] [Related]
9. A Meta-analysis of Randomised Controlled Trials Comparing Combination Therapy as Second-line Treatment With Monotherapy in Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation.
Zhao KX; Zhang YF; Zheng L; Pan YF; He ZH
Am J Clin Oncol; 2023 Dec; 46(12):551-558. PubMed ID: 37779240
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis.
Sheng J; Yang Y; Ma Y; Yang B; Zhang Y; Kang S; Zhou T; Hong S; Qin T; Hu Z; Fang W; Huang Y; Zhang L
PLoS One; 2015; 10(6):e0127306. PubMed ID: 26034985
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tyrosine kinase inhibitors in patients with advanced or metastatic sarcomas after prior chemotherapy: A meta-analysis.
Li W; Liu L; Liang Z; Lai H; Wu J; Zhang H; Fang C
Medicine (Baltimore); 2024 Mar; 103(11):e37423. PubMed ID: 38489731
[TBL] [Abstract][Full Text] [Related]
12. Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis.
Mo Z; Ye M; He H; Huang X; Guo W; Zhao Z; Li Y; Wei S
Clin Med Insights Oncol; 2023; 17():11795549231215968. PubMed ID: 38107371
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis.
Ye S; Li J; Hao K; Yan J; Zhou H
Sci Rep; 2016 Oct; 6():35770. PubMed ID: 27786238
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR-TKIs: A Systematic Review and Meta-Analysis.
Tang M; Gao X; Sun H; Tian S; Dong J; Liu Z; Liu W
J Oncol; 2021; 2021():6688346. PubMed ID: 33542732
[TBL] [Abstract][Full Text] [Related]
15. Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice.
Song X; Cao L; Ni B; Wang J; Qin X; Sun X; Xu B; Wang X; Li J
Front Pharmacol; 2023; 14():1090500. PubMed ID: 37089959
[TBL] [Abstract][Full Text] [Related]
16. Selection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase Inhibitors.
Zwitter M; Rossi A; Di Maio M; Perme MP; Lopes G
Radiol Oncol; 2017 Sep; 51(3):241-251. PubMed ID: 28959160
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab.
Rosell R; González-Cao M
Nat Rev Clin Oncol; 2024 Mar; 21(3):169-170. PubMed ID: 38057404
[No Abstract] [Full Text] [Related]
18. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients.
Wang R; Zhang Y; Pan Y; Li Y; Hu H; Cai D; Li H; Ye T; Luo X; Zhang Y; Li B; Shen L; Sun Y; Chen H
Oncotarget; 2015 Oct; 6(33):34300-8. PubMed ID: 26486077
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.
Rounds A; Kolesar J
Am J Health Syst Pharm; 2015 Nov; 72(21):1851-5. PubMed ID: 26490818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
